JTCS Concomitant Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Adam E. Saltman
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saltman, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saltman, A. E.
Related Collections
Right arrow Cardiac - pharmacology
Right arrow Coronary disease
Right arrow Electrophysiology - arrhythmias
Right arrowRelated Article

J Thorac Cardiovasc Surg 2003;125:1202-1203
© 2003 The American Association for Thoracic Surgery

Editorials

Is it time to choose amiodarone for postoperative atrial fibrillation?

Adam E. Saltman, MD

From the Department of Surgery, Division of Cardiothoracic Surgery, University of Massachusetts Memorial Medical Center, Worcester, Mass.

Received for publication Dec 3, 2002. Accepted for publication Dec 16, 2002. Address for reprints: A. E. Saltman, MD, Department of Surgery, Division of Cardiothoracic Surgery, University of Massachusetts Memorial Medical Center, 55 Lake Ave N S3-747, Worcester, MA 01655 (E-mail: aesmdphd@hotmail.com).

The first 20% of the full text of this article appears below.

See related article on page 1420.

Despite the astonishing advances that have been made in cardiac surgery over the past 40 years, new-onset atrial fibrillation remains its most common complication. Long thought a nuisance, it has now been clearly shown to increase length of stay, intensive care unit utilization, morbidity, and even long-term mortality. It occurs in anywhere from 15% to 40% of patients and little progress has been made in our understanding, prevention, or treatment of it.

Yagdi and colleaguesGo 1 have presented elsewhere in this issue of the Journal their study on the use of amiodarone to prevent new-onset postoperative atrial fibrillation (PAF) in patients undergoing coronary artery bypass grafting. They studied a group of 157 subjects, randomly assigned to receive amiodarone after surgery or their usual care without amiodarone. The drug was administered as an intravenous infusion over 2 days, beginning immediately after surgery, followed by declining oral dosing . . . [Full Text of this Article]


Related Article

Amiodarone reduces the incidence of atrial fibrillation after coronary artery bypass grafting
Tahir Yagdi, Sanem Nalbantgil, Fatih Ayik, Anil Apaydin, Fatih Islamoglu, Hakan Posacioglu, Tanzer Calkavur, Yuksel Atay, and Suat Buket
J. Thorac. Cardiovasc. Surg. 2003 125: 1420-1425. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. Yazigi, F. Haddad, S. Madi-Jebara, G. Sleilaty, and V. A. Jebara
Amiodarone for postoperative atrial fibrillation
J. Thorac. Cardiovasc. Surg., January 1, 2004; 127(1): 304 - 304.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The American Association for Thoracic Surgery.